*Corresponding author. Tel: !390226437961; Fax: !390226437903; Email: nozza.silvia@hsr.it Sir, Current guidelines recommend ART during primary HIV infection (PHI). [1] [2] [3] Before initiating ART in a person with HIV-1 infection, genotypic antiretroviral (ARV) drug resistance testing should be performed to guide selection of the ARV regimen; if therapy is started before the results of drug resistance testing are available, Department of Health and Human Services guidelines 1 recommend the use of a boosted PI-based regimen (darunavir/ ritonavir) because resistance to PIs emerges slowly and clinically significant transmitted resistance to PIs is uncommon. This choice is due to the finding that transmitted virus may be resistant to at least one ARV drug; data from the USA demonstrate that transmitted virus may be resistant to at least one ARV drug in up to 16% of patients. 4 In Italy, the prevalence of drug resistance mutations has been significantly reduced in recent years (8.2%). 5 We have no data about the efficacy of an integrase inhibitor (InSTI)-containing regimen in PHI; the rapid decrease in HIV-RNA could be associated with HIV-DNA decay with implications for HIV reservoir control. 6 The aim of this study was to assess the efficacy of elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate (EVG/C/FTC/TDF) in patients with PHI compared with patients with recent HIV infection (RHI).
We conducted a retrospective study on PHI or RHI patients, followed at the Infectious Diseases Department, San Raffaele Scientific Institute (IDD-HSR), Milan, Italy, who started ART with EVG/C/FTC/TDF. Patients did not sign written consent for the retrospective study; data recorded in the database of the IDD-HSR were used for the analyses. RHI patients included subjects with HIV infection within 1 year since the last negative HIV serological test who started ART within 1 year from HIV diagnosis. Results were expressed as median (IQR) or frequency (%). v 2 or the Wilcoxon rank sum test were used to compare groups. Kaplan-Meier curves were calculated to estimate the time to undetectable viral load (HIV-RNA , 50 copies/mL) and compared by use of the log-rank test. The Cox proportional hazard model was used to estimate factors [including age, baseline CD4!, baseline HIV-RNA, group of patients (PHI versus RHI)] associated with time to undetectable viral load.
Forty-seven patients were enrolled: 23 (49%) PHI and 24 (51%) RHI. Demographic and baseline clinical characteristics are shown in Table 1 . No differences between the two groups were recorded and no major genotypic mutations for InSTIs were found. One patient in the PHI group and one in the RHI group had minor InSTI mutations; one patient in the RHI group had major NRTI mutations.
Over a median follow-up of 64 (47-78) weeks in the PHI group and 37 (23-69) weeks in the RHI group (P " 0.136), time to undetectable viral load was not significantly different between groups; at weeks 4, 12, 24 and 48, the probabilities of undetectable viral load were 5% versus 8%, 35% versus 54%, 85% versus 79% and 100% versus 100% among the PHI and RHI groups, respectively (log-rank test: P " 0.695). Based on multivariate analysis, time to undetectable viral load was delayed in subjects with higher baseline HIV-RNA [adjusted HR (per 0.5 log 10 copies/mL higher) " 0.64, 95% CI 0.47 to 0.88, P " 0.006]; other factors were all not significant.
At week 4 viral decrease was 3.2 (2.5-3.7) log 10 copies/mL in the PHI group and 3.1 (2.9-3.2) log 10 copies/mL in the RHI group (P " 0.622).
At week 48 the CD4! cell count increased in both groups; the CD4! change during follow-up was different between the two groups, with a higher CD4! gain of 350 (207-422) cells/mm 3 in the PHI group versus 251 (181-445) cells/mm 3 in the RHI group, although this was not statistically significant (P " 0.450).
At week 48 the CD4/CD8 ratio increased in both groups without differences between the groups (P " 0.815); we observed a CD4/CD8 gain of 0.35 (0.26-0.68) in the PHI group versus 0.52 (0.21-0.67) in the RHI group. At baseline no patients in the PHI group and two patients in the RHI group had a CD4/CD8 ratio .1; eight (35%) patients in the PHI group and six (25%) patients in the RHI group reached a CD4/CD8 ratio .1 (P " 0.534).
Treatment was well tolerated, without grade 3 or 4 adverse events. No significant difference between the two groups was found for the 48 week trend of bone marrow function, AST, ALT and creatine phosphokinase values, glucose profile (fasting glucose, fasting insulin) and lipid profile (total cholesterol, LDL and HDL cholesterol, triglycerides) (data not shown).
At week 48 renal function was normal in both groups: we observed an estimated glomerular filtration rate (eGFR) of 93 (85-114) mL/min/1.73 m 2 in the PHI group versus 99 (82-101) mL/min/1.73 m 2 in the RHI group (P " 0.829). No patients reached a pathological value of eGFR or had tubulopathy.
Virological efficacy appeared to be similar in PHI and RHI patients treated with EVG/C/FTC/TDF; patients treated during PHI started therapy without waiting for genotypic ART resistance. In patients diagnosed with an acute or recent HIV infection from 2000 to 2010 the overall prevalence of any drug resistance mutation was 14%; NRTI, NNRTI and major PI resistance mutations were detected in 7%, 7% and 3% of patients, respectively, but in the last years investigated the prevalence descreased. 5 The low prevalence of NRTI mutations in the 47 patients of the present study could explain the high virological response and support the low prevalence of NRTI mutations in new early ARV-naive patients.
We observed a trend to better immunological recovery in the PHI group, in terms of absolute CD4 count, although this was not significant, probably due to the small sample size. Previous studies showed that a restoration of CD4! T cell counts occurs in the 4 month time window after HIV-1 infection, and initiation of ARV during this period is associated with an enhanced likelihood of recovery of CD4! counts; 7 in the SPARTAC trial initiation of ARV maintained a CD4! count of .350 cells/mm 3 . 8 In our study a CD4/CD8 ratio of .1 was reached more frequently in PHI than in RHI patients; these data are in agreement with the SPARTAC trial, but patients enrolled in the SPARTAC trial had baseline characteristics and inclusion criteria similar to the current definition of RHI. 9 Safety was comparable to that in a randomized study. 10 In particular, we did not observe relevant kidney toxicity.
In conclusion, our study shows similar virological efficacy and safety of EVG/C/FTC/TDF in the treatment of both PHI and RHI patients. Rapid decay in PHI and RHI is important because most new infections are contracted by people in this phase. The results could support the use of EVG/C/FTC/TDF in this setting in order to prevent new HIV infections.
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